Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.38 |
| ▸ | ALB | P02768 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 12/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | POLG | P54098 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19315931 | 1.00 | FGFR1 (0.39) | FGFR1PDE3ALMNACACNA1FALB | |
| SCHEMBL19249190 | 1.00 | FGFR1 (0.39) | FGFR1PDE3ALMNACACNA1FALB | |
| SCHEMBL19315641 | 1.00 | FGFR1 (0.39) | FGFR1PDE3ALMNACACNA1FALB | |
| SCHEMBL19206596 | 0.91 | PDE3A (0.39) | FGFR1PDE3ALMNACACNA1FALB | |
| SCHEMBL17725153 | 0.82 | PDE3A (0.33) | FGFR1PDE3ALMNACACNA1FALB | |
| SCHEMBL19206474 | 0.81 | LMNA (0.32) | FGFR1PDE3ALMNACACNA1FALB | |
| SCHEMBL17725025 | 0.80 | ABL1 (0.48) | LMNAMAPTSTING1 | |
| SCHEMBL22341367 | 0.78 | CACNA1F (0.31) | FGFR1PDE3ALMNACACNA1FALB | |
| SCHEMBL21275980 | 0.78 | CACNA1F (0.31) | FGFR1PDE3ALMNACACNA1FALB | |
| SCHEMBL17725082 | 0.78 | CACNA1F (0.31) | FGFR1PDE3ALMNACACNA1FALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3214090-B1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORP (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-10385089-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | FUJIFILM CORPORATION (JP) | 2019-08-20 | — | — | US | disclosed |
| US-10385089-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | FUJIFILM CORPORATION (JP) | 2019-08-20 | — | — | US | disclosed |
| US-20180319834-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2018-11-08 | — | — | US | disclosed |
| US-10059734-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | FUJIFILM CORPORATION (JP) | 2018-08-28 | — | — | US | disclosed |
| EP-3214090-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | Fujifilm Corporation (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-3214090-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | Fujifilm Corporation (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
| WO-2016068341-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | 富士フイルム株式会社 | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319834-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | SLC11A2, RNASE1, KRAS | FGFR1 1788/4885PDE3A 3060/4885LMNA 4093/4885 |
| US-10385089-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | SLC11A2, RNASE1, KRAS | FGFR1 1788/4885PDE3A 3060/4885LMNA 4093/4885 |
| US-10059734-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | SLC11A2, RNASE1, TYMP | FGFR1 1472/4885PDE3A 3093/4885LMNA 4144/4885 |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | SLC11A2, RNASE1, TYMP | FGFR1 1472/4885PDE3A 3093/4885LMNA 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.